NVCT earnings date and last-quarter result: last quarter miss, P/E -14.73. Updated 2026-07-23.
Nuvectis Pharma (NVCT) Research Hub
Nuvectis Pharma (NVCT) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-10-26, shares last closed at 18.49 USD (-7.78%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -14.73, market cap 0.51B. This hub links to the full technical, earnings and options research available for NVCT.
Last updated 2026-10-26 · Source: end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 18.49 USD (-7.78%) |
| 52-week range | 10.73 USD – 28.37 USD |
| Trend regime | Range |
| 14-day RSI | 42.7 (Bearish) |
| Trailing P/E | -14.73 |
| Market cap | 0.51B |
| Dividend yield | 0.00% |
Available research for NVCT
Covered Call on NVCT: how it works, illustrative setup around the real 18.49 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on NVCT: how it works, illustrative setup around the real 18.49 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on NVCT: how it works, illustrative setup around the real 18.49 USD price, max profit/loss, breakeven and when to use it. Educational.
NVCT technical analysis: range, last 18.49 USD, RSI 42.7, 52w range 10.73 USD–28.37 USD, real support/resistance. Updated 2026-10-26.
More on SniperIQ
Frequently asked questions
What sector is NVCT in?
Nuvectis Pharma (NVCT) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.
Is NVCT in an uptrend or downtrend?
As of 2026-10-26, NVCT is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is NVCT's trailing P/E ratio?
NVCT's trailing P/E is -14.73, with a market cap of 0.51B. See the earnings research page for full valuation detail.